Radium-223 (Xofigo®)

Assessment Status Assessment Process Complete
Drug Radium-223
Brand Xofigo®
Indication For the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.
Assessment Process
Rapid review commissioned 28/11/2013
Rapid review completed 23/12/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 11/04/2014
NCPE assessment completed 12/12/2014
NCPE assessment outcome Reimbursement not Recommended

The NCPE does not recommend reimbursement of radium-223 at the submitted price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations December 2015.